title: Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of sequential transcatheter arterial chemoembolization (TACE )and portal vein embolization (PVE) before major hepatectomy for patients with hepatocellur carcinoma (HCC).
  
  
  METHODS
  In this retrospective case-control study, data were collected from patients who underwent sequential TACE and PVE prior to major hemihepactectomy. Liver volumes were measured by computed tomography volumetry before TACE, and preoperation to assess degree of future remnant liver (FRL) hypertrophy and to check whether intro- or extrohepatic metastasis existed. Liver function was monitored by biochemistry after TACE, prior to and after major hepatectomy.
  
  
  RESULTS
  Mean average FRL volume increased 32.3-71.4% (mean 55.4%) compared with preoperative FRL volume. After TACE, liver enzymes were elevated, but returned to normal in four weeks. During PVE and resection, no patient had intro- or extrohepatic metastasis.
  
  
  CONCLUSIONS
  Sequential TACE and PVE is an effective method to improve resection opportunity, expand the scope of surgical resection, and greatly reduce postoperative intra- and extrahepatic metastasis.
authors.affiliation: Department of Interventional Radiology, Subei People Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University, Yangzhou, China E-mail : whycn7@sina.com, huangxinen06@aliyun.com.
authors.forename: Chuan
authors.initials: C
authors.lastname: Xu
authors.forename: Peng-Hua
authors.initials: PH
authors.lastname: Lv
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Shu-Xiang
authors.initials: SX
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Sun
authors.forename: Fu-An
authors.initials: FA
authors.lastname: Wang
authors.forename: Li-Fu
authors.initials: LF
authors.lastname: Wang
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000628:therapy*; D016022:Case-Control Studies; D002404:Catheterization; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006499:Hepatic Artery / Q000473:pathology / Q000601:surgery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011169:Portal Vein / Q000473:pathology / Q000601:surgery*; D011300:Preoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D012449:Safety